Official management and treatment guidelines for IgG4-related disease

Key recommendations from the consensus guidelines

Evaluate the full clinical picture

Begin with a complete assessment that includes history, physical examination, targeted laboratory studies, and appropriate imaging. IgG4-RD is often multisystem, and clinically silent organ involvement is common, so physicians should actively look beyond the presenting organ.

Confirm the diagnosis with biopsy

Whenever feasible, obtain tissue from an affected organ to support the diagnosis. Biopsy is critical not only for confirming IgG4-RD, but for excluding malignancy, infection, vasculitis, lymphoma, and other conditions that can present in similar ways.

Use clinicopathologic correlation

Histopathology must be interpreted in the context of the patient’s overall clinical phenotype. Even highly suggestive tissue findings are not fully diagnostic without the right clinical setting, and IgG4-positive plasma cells alone are not specific for IgG4-RD.

Do not rely on serum IgG4 alone

Serum IgG4 concentration can support clinical suspicion, but it should never be used as a stand-alone diagnostic test. Normal levels do not exclude the disease, and elevated levels do not establish it.

Treat active, symptomatic disease promptly

Patients with active, symptomatic IgG4-RD should generally be treated without delay. Early treatment is particularly important when there is a risk of organ dysfunction, progression to fibrosis, or irreversible damage.

Recognize organ-threatening disease early

Some patients require urgent treatment because of the organ involved, the pace of progression, or the risk of permanent injury. Physicians should maintain a low threshold for intervention when vital organ function may be compromised.

Use glucocorticoids as first-line induction therapy

Glucocorticoids remain the standard first-line treatment for induction of remission in most patients with active disease. In routine practice, this means steroids are usually the initial therapeutic bridge to disease control unless contraindications or special circumstances dictate otherwise.

Individualize steroid-sparing therapy

Not every patient requires a steroid-sparing agent at diagnosis, but some clearly do. The decision should be guided by disease extent, organ involvement, relapse risk, prior treatment history, anticipated steroid toxicity, and the need for a more durable remission strategy.

Consider maintenance treatment in selected patients

Maintenance therapy is appropriate for some patients after remission induction, particularly those with multiorgan disease, prior relapse, or high-risk organ involvement. The goal is not simply disease suppression, but prevention of recurrent inflammation and cumulative organ damage.

Re-treat relapse decisively

Disease relapse usually warrants re-induction therapy, often again with glucocorticoids. A relapse should also prompt reassessment of the overall treatment plan, because recurrent disease often signals the need for a more structured maintenance approach.

Escalate therapy when relapse risk is high

After relapse, clinicians should strongly consider steroid-sparing treatment for longer-term disease control. This is especially relevant in patients whose disease is steroid-responsive but not steroid-sustainable.

Monitor with more than one measure

Follow-up should be based on a combination of symptoms, examination findings, laboratory trends, imaging, and organ-specific assessment. No single biomarker is sufficient to capture disease activity across all patients or all organ systems.